CVRx (CVRX) – Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for CVRx (NASDAQ: CVRX):

  • 11/15/2026 – CVRx was downgraded by Wall Street Zen from “sell” to “strong sell”.
  • 11/13/2026 – CVRx had its price target lowered by Cantor Fitzgerald to $2.00. They now have an “overweight” rating on the stock.
  • 11/7/2026 – CVRx was downgraded by Wall Street Zen from “hold” to “sell”.
  • 11/6/2026 – CVRx was downgraded by William Blair from “outperform” to “market perform”.
  • 11/6/2026 – CVRx had its price target lowered by Lake Street Capital from $3.50 to $1.50. They now have a “hold” rating on the stock.
  • 11/6/2026 – CVRx was downgraded by Canaccord Genuity Group from “buy” to “hold”. They now have a $2.00 price target on the stock, down from $5.00.
  • 10/30/2026 – CVRx had its “sell (e+)” rating reaffirmed by Weiss Ratings.
  • 10/10/2026 – CVRx was upgraded by Wall Street Zen from “sell” to “hold”.
  • 9/22/2026 – CVRx was given a new $5.00 price target by Canaccord Genuity Group.
  • 9/20/2026 – CVRx was downgraded by Wall Street Zen from “hold” to “sell”.

CVRx Price Performance

Shares of NASDAQ CVRX traded down $0.00 during mid-day trading on Tuesday, hitting $0.61. 637,316 shares of the stock traded hands, compared to its average volume of 556,189. The company has a debt-to-equity ratio of 4.24, a current ratio of 6.80 and a quick ratio of 5.71. CVRx, Inc. has a twelve month low of $0.57 and a twelve month high of $10.28. The company has a market cap of $17.41 million, a PE ratio of -0.30 and a beta of 0.81. The firm has a 50 day simple moving average of $1.80 and a two-hundred day simple moving average of $4.97.

CVRx (NASDAQ:CVRX – Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.02). CVRx had a negative return on equity of 208.45% and a negative net margin of 88.28%. The firm had revenue of $13.83 million for the quarter, compared to the consensus estimate of $13.93 million. As a group, equities research analysts forecast that CVRx, Inc. will post -2.04 EPS for the current fiscal year.

CVRx, Inc. is a medical technology company that develops and commercializes implantable neuromodulation devices for cardiovascular conditions. Its technology is designed to influence the autonomic nervous system, which helps regulate functions such as heart rate and blood pressure. The company’s primary product is Barostim, an implantable system that delivers electrical signals to baroreceptors in the carotid artery. In the United States, Barostim is approved to improve symptoms for certain patients with heart failure who remain symptomatic despite medical therapy.

Read More

Receive News & Ratings for CVRx Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVRx Inc and related companies with MarketBeat.com's FREE daily email newsletter.